Dianthus Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018 - 2016
Net Income	-43.56	-28.48	-71.14	-74.94	-76.77	Upgrade
Depreciation & Amortization	0.36	0.15	2.02	1.98	1.84	Upgrade
Share-Based Compensation	2.9	1.52	10.31	9.94	10	Upgrade
Other Operating Activities	3.44	-2.26	-0.72	-1.01	7.82	Upgrade
Operating Cash Flow	-36.86	-29.07	-59.53	-64.02	-57.1	Upgrade
Capital Expenditures	-0.11	-0.14	-1.26	-0.4	-3.06	Upgrade
Change in Investments	20.36	-59.68	44.69	-10.24	4.59	Upgrade
Investing Cash Flow	20.25	-59.82	43.43	-10.64	1.53	Upgrade
Share Issuance / Repurchase	0.01	0	89.9	68.04	62.3	Upgrade
Other Financing Activities	133.57	96.68	-0.3	-0.3	-	Upgrade
Financing Cash Flow	133.57	96.68	89.6	67.74	62.3	Upgrade
Net Cash Flow	116.97	7.79	73.5	-6.92	6.73	Upgrade
Free Cash Flow	-36.97	-29.21	-60.8	-64.42	-60.16	Upgrade
Free Cash Flow Margin	-1308.24%	-455.18%	-	-	-	Upgrade
Free Cash Flow Per Share	-7.17	-33.41	-17.70	-23.47	-26.01	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).